Literature DB >> 26223768

Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.

Michelle Spaan1, Gertine van Oord1, Kim Kreefft1, Jun Hou1, Bettina E Hansen1, Harry L A Janssen2, Robert J de Knegt1, Andre Boonstra1.   

Abstract

BACKGROUND: Chronic hepatitis C virus (HCV) infection is a global health problem, resulting in liver failure, hepatocellular carcinoma, and liver-related death. Natural killer (NK) cells are innate immune cells, and their activity is known to correlate to viral treatment response of HCV. In this study, we investigate the immune effects of viral load decline with direct-acting antivirals (DAAs) in blood.
METHODS: Twelve patients with chronic HCV were treated with asunaprevir and daclatasvir, and peripheral blood was analyzed at various time points during therapy.
RESULTS: In line with previous studies, we confirmed restoration of HCV-specific T-cell frequency upon viral load decline. In addition, we show that serum interferon (IFN)-γ inducible-protein 10, interleukin (IL)-12p40, and IL-18 levels decreased early after start of therapy. Surface expression of activation receptors NKp30, NKp46, and inhibitory receptor NKG2A on blood NK cells reduced during therapy. In addition, the expression of TRAIL on NK cells was reduced during IFN-free therapy, suggesting a decrease in TRAIL-mediated killing by NK cells.
CONCLUSIONS: We show that viral load decline as a consequence of treatment with novel DAAs in chronic HCV patients reduces serum levels of NK cell-stimulating cytokines and causes correction of the altered NK cell phenotype observed in chronic HCV patients. CLINICAL TRIALS REGISTRATION: NCT02282709.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  DAA therapy; HCV-specific T cells; TNF-related apoptosis-induced ligand (TRAIL); interferon-stimulated genes (ISGs); viral hepatitis

Mesh:

Substances:

Year:  2015        PMID: 26223768     DOI: 10.1093/infdis/jiv391

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C.

Authors:  Toshihiro Kawaguchi; Tatsuya Ide; Hironori Koga; Reiichiro Kondo; Ichiro Miyajima; Teruko Arinaga-Hino; Reiichiro Kuwahara; Keisuke Amano; Takashi Niizeki; Masahito Nakano; Ryoko Kuromatsu; Takuji Torimura
Journal:  Clin J Gastroenterol       Date:  2017-10-29

Review 2.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

3.  A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Authors:  Xiao Liu; Xiaoqiong Duan; Jacinta A Holmes; Wenting Li; Sae Hwan Lee; Zeng Tu; Chuanlong Zhu; Shadi Salloum; Anna Lidofsky; Esperance A Schaefer; Dachuan Cai; Shilin Li; Haoju Wang; Yongfu Huang; Yongju Zhao; Ming-Lung Yu; Zhiwen Xu; Limin Chen; Jian Hong; Wenyu Lin; Raymond T Chung
Journal:  Hepatology       Date:  2019-02-13       Impact factor: 17.425

4.  Different effects of the immunostimulatory drug Stimforte on infections of hepatitis C virus and herpes simplex virus type 1.

Authors:  D G Maldov; V L Andronova; S S Grigorian; E I Isaeva; P G Deryabin; D V Mishin; A A Balakina; A V Ilyichev; A A Terentyev; G A Galegov
Journal:  Dokl Biol Sci       Date:  2018-01-04

5.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

Review 6.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

Review 7.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

8.  Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.

Authors:  Anna Mania; Mariusz Kaczmarek; Paweł Kemnitz; Katarzyna Mazur-Melewska; Magdalena Figlerowicz; Jan Sikora; Wojciech Służewski; Jan Żeromski
Journal:  Med Microbiol Immunol       Date:  2017-11-08       Impact factor: 3.402

9.  Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Authors:  Elisavet Serti; Heiyoung Park; Meghan Keane; Ashley C O'Keefe; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gut       Date:  2016-01-04       Impact factor: 23.059

10.  Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.

Authors:  Dong Hyun Sinn; Seung Up Kim; Hye Kyung Hyun; Eun Ju Cho; Soo Young Park; Young Mi Hong; Soon Sun Kim; Hwi Young Kim; Nae-Yun Heo; Jung Gil Park; Wonseok Kang; Song Won Jeong; Myeong Jun Song; Hana Park; Danbi Lee; Yong Sun Lee; Sung Bum Cho; Chan Sik An; Hyung Jin Rhee; Hyun Woong Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Won Young Tak; Young Oh Kweon; Ki Tae Yoon; Mong Cho; Jae Youn Cheong; Seung Ha Park
Journal:  Dig Dis Sci       Date:  2020-08-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.